SCHEMBL16294271

SCHEMBL16294271

CC(NC(=O)c1[c]cccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.47
ALDH1A1 P00352 1/20 0.46
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
MME P08473 3/20 0.43
ANPEP P15144 1/20 0.43
ECE1 P42892 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
BBOX1 O75936 2/20 0.43
EGLN1 Q9GZT9 2/20 0.43
FTO Q9C0B1 1/20 0.43
CA2 P00918 2/20 0.42
CA1 P00915 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1444015 0.84 ALOX15 (0.41) ALDH1A1MEN1TSHRKMT2ALMNA
SCHEMBL9478955 0.83 KMT2A (0.36) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL8125303 0.79 KMT2A (0.34) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1903196 0.79 KMT2A (0.34) ALDH1A1MEN1TSHRKMT2ASMN1; SMN2
SCHEMBL28070090 0.76 EPHX2 (0.50) CA2CA1LMNA
SCHEMBL8119388 0.75 PGR (0.40) ALDH1A1MEN1TSHRKMT2ASMN1; SMN2
SCHEMBL15527899 0.75 HPGD (0.34) ALDH1A1MEN1TSHRKMT2AMME
SCHEMBL295086 0.74 GAA (0.42) ALDH1A1TSHRHDAC8HDAC6SMN1; SMN2
SCHEMBL11111257 0.74 ALDH1A1 (0.56) LTA4HALDH1A1MEN1TSHRKMT2A
SCHEMBL11111255 0.74 ALDH1A1 (0.56) LTA4HALDH1A1MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014200885-A1 PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2014-12-18 WO claimed
WO-2014200885-A1 PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2014-12-18 WO disclosed